Avirtaz

Every registration of this product has been cancelled.

No structure available

This product's active ingredient could not be matched to a single known compound.

Registration

Applicants: 1
Registrations: 2

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Viatris Healthcare (Pty) LtdCancelled	Avirtaz	150 mg, 300 mg	460970, 460971	Not determined	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Avirtaz 150 MG EACH CAPSULE CONTAINS ATAZANAVIR 150,0 mg	150 mg	46097046/20.2.8/0970	Cancelled	Not determined	PI PIL
Avirtaz 300 MG EACH CAPSULE CONTAINS ATAZANAVIR 300,0 mg	300 mg	46097146/20.2.8/0971	Cancelled	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

S4: Atazanavir
Consolidated Schedules 06 July 2026, line 5370
S4: Ritonavir
Consolidated Schedules 06 July 2026, line 7820

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading Wikipedia summary

SAHPRA documents

Professional information (PI)For healthcare professionalsAvirtaz 150 MG, Viatris Healthcare (Pty) Ltd. SAHPRA's document for AVIRTAZ Patient information leaflet (PIL)For patients and carersAvirtaz 150 MG, Viatris Healthcare (Pty) Ltd. SAHPRA's document for AVIRTAZ

These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles